

Our Ref: 297/2023  
JUNE 2023

## Re: Your request made under the Freedom of Information Act 2000

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

### Multiple myeloma 1890

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- Belantamab Mafodotin [Blenrep]
  - Bortezomib [Velcade] monotherapy or with dexamethasone
  - Bortezomib, thalidomide and dexamethasone [VTD]
  - Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
  - Carfilzomib [Kyprolis] and dexamethasone
  - Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
  - Daratumumab [Darzalex] monotherapy
  - Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
  - Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
  - Elranatamab
  - Idecabtagene vicleuceel [Abecma]
  - Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
  - Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
  - Lenalidomide [Revlmid] monotherapy
  - Lenalidomide [Revlmid] and dexamethasone
  - Pomalidomide [Imnovid] and dexamethasone
  - Selinexor and dexamethasone
  - Talquetamab
  - Teclistamab [Tecvayli]
  - Any other systemic anti-cancer therapy
- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Our Ref: 297/2023  
JUNE 2023